cerebrovascular accident, including transient ischemic attacks within the past 6 months.
No history of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastases
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Arterial thromboembolic or embolic events such as myocardial infarction, cerebrovascular accident, including transient ischemic attacks within 6 months prior to first study treatment
Thrombolic or embolic events (except deep vein thrombosis [DVT] or pulmonary embolus) such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months; hepatic portal vein thrombus is not considered an exclusion criterion
No history of cerebrovascular accident or transient ischemic attacks
Thromboembolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
No history of cerebrovascular accident or transient ischemic attacks within the past 6 months from registration
Thrombolytic, embolic, venous, or arterial events such as cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
No history of cerebrovascular accident or transient ischemic attacks within the past 6 months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months
Has an unstable neurological disease (e.g. cerebrovascular accident [including transient ischemic attacks (TIAs)]) within the 3 months before signing of informed consent
History of any arterial thrombotic event within 6 months prior to enrollment.
History of bleeding disorders or thromboembolic events in prior 3 months
Women with active liver disease or thromboembolic disorder.
Patients will be excluded if any of the following are present, evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis; History (within 6 months prior to study enrollment) of arterial thromboembolic events, including transient ischemic attack (TIA) or cerebrovascular accident (CVA); history (within 6 months prior to study enrollment) of pulmonary embolism, deep venous thrombosis (DVT), or other venous thromboembolic event; history of clinically significant bleeding within 6 weeks prior to study enrollment.
Patients with prior history of a thromboembolic event within the last 12 months that is not being treated with systemic anticoagulation are excluded
Any subject who, in the opinion of the principal investigator (PI) is at risk for thromboembolic events
History of thromboembolic events (including both pulmonary embolism and deep venous thrombus but not including tumor thrombus) within the last 6 months
Patients with a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
Uncontrolled thromboembolic events or recent severe hemorrhage
>= grade 3 thromboembolic event in the last 6 months
History of any arterial thromboembolic event within 3 months prior to first dose of investigational product
Recent occurrence (within 3 to 6 months) of a major thromboembolic event, such as pulmonary embolism or proximal deep vein thrombosis, unless stable on (>1 month) therapeutic anticoagulation (aspirin <325 milligrams (mg) daily or low-molecular-weight heparin [LMWH]). Participants with a history of clinically non-significant thromboembolic events, not requiring anticoagulation, are allowed on study.
Any history of arterial or venous thrombosis/thromboembolic event, including pulmonary embolism within the past 12 months prior to registration.
Patients with thromboembolic disease and on anticoagulation
Willing and able to receive adequate prophylaxis and/or therapy for thromboembolic events
Has a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period
Current thrombotic or hemorrhagic disorder/event or history of prior event within 6 months of start of screening
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
History of arterial thromboembolic events in the past 3 months and of venous thromboembolic events in the past month
Arterial or venous thromboembolic events within 6 months of study enrollment
History of arterial thromboembolic event
Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
History of arterial thromboembolic events or symptomatic pulmonary embolism within the past 6 months
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
Prior history of a thromboembolic event within the last two years and not currently on systemic anticoagulation
Subject has a significant history of cardiovascular disease (e.g., myocardial infarction [MI], thrombotic or thromboembolic event in the last 6 months)
Subjects must not have a history of thromboembolic disorder or cerebral vascular disease
Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment.
A history of thromboembolic disorder
Recent arterial thromboembolic event within the previous 6 months
History of arterial thromboembolic events
History of cardiovascular disease (e.g., myocardial infraction [MI], thrombotic or thromboembolic event in the last 6 months)
History of thromboembolic episodes =< 3 months prior to registration
Patients with evidence of active bleeding, intratumoral hemorrhage, or bleeding diathesis are not eligible:\r\n* History (within 180 days prior to study enrollment) of arterial thromboembolic events, including transient ischemic attack (TIA) or cerebrovascular accident (CVA)\r\n* History (within 180 days prior to study enrollment) of pulmonary embolism, deep vein thrombosis (DVT), or other venous thromboembolic event\r\n* History of hemoptysis within 42 days prior to study enrollment
Patients who have had a thromboembolic event that is not line-related are excluded
The participant experienced any arterial thromboembolic event within 6 months.
The participant experienced any Grade 3 or 4 venous thromboembolic event that is not adequately treated.
History of arterial thromboembolic events or symptomatic pulmonary embolism within 6 months of study enrollment
be able and willing to receive adequate prophylaxis and/or therapy for thromboembolic events
Have active, acute, or chronic clinically significant infections or bleeding within the last 6 months or previous thromboembolic or hemorrhagic events during anti angiogenic therapy.
Patients with history of thrombophlebitis within the past 2 years or ongoing thromboembolic disorders
have experienced any arterial thromboembolic event within 6 months prior to enrollment
have experienced any Grade 3 or 4 venous thromboembolic event that is considered by the investigator to be life threatening or that is symptomatic and not adequately treated by anticoagulation therapy, within 6 months prior to enrollment
Evidence or history of thromboembolic, venous, or arterial events within the past 3 months
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
Uncontrolled thromboembolic or hemorrhagic disorders.
Subjects who are at a risk for a thromboembolic event and are not willing to take prophylaxis for it.
High risk of developing thromboembolic events, who are unwilling to take venous thromboembolism prophylaxis.
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
History of arterial thromboembolic (arterial blood clot) or hemorrhagic event with the exception of patients with pulmonary embolism stable on an anticoagulation regimen
Patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation and who meet any of the following criteria:\r\n* Have been on a stable dose of anticoagulation for < 1 month\r\n* Have had a grade 2, 3 or 4 hemorrhage in the last 30 days\r\n* Are experiencing continued symptoms from their venous thromboembolic event (e.g. continued dyspnea or oxygen requirement); NOTE: Patients who have had a venous thromboembolic event but do not meet any of the above three criteria are eligible for participation
Has a history of thromboembolic or cerebrovascular events within 6 months prior to registration
History of any of the following during first-line therapy with a bevacizumab-containing regimen: arterial thrombotic/thromboembolic event, bowel perforation, Grade 4 hypertension, Grade 3 proteinuria or Grade 3 - 4 bleeding event.
Thrombotic/ thromboembolic event requiring systemic anticoagulation within 90 days prior to enrollment
History of thrombosis or thromboembolic event within last 30 days prior to study entry
Low-dose aspirin (=< 325 mg/day) may be continued in subjects at higher risk for arterial thromboembolic disease
At high risk for a venous thromboembolic event (VTE) and not willing to take VTE prophylaxis
Patients with evidence of active thromboembolic disease, recent history of thromboembolic disease within the past 6 months, or risk factors for thromboembolic disease (excluding thrombosis of a central line)
History of thromboembolic disease within the past 6 months regardless of anti-coagulation
History of clinically significant hemorrhagic or thromboembolic event in the past 6 months
History of medically significant thromboembolic events or bleeding diathesis within the past 6 months
History of Grade 3 or greater thromboembolic events in the prior 12 months
Thromboembolic events, stroke, or ST-elevated myocardial infarction within 7 days of surgery.
History of severe haemorrhagic or thromboembolic event in the past 12 months
Thromboembolic or myocardial infarction event within 6 months
Diagnosed venous thromboembolic disease within the preceding 6 months (patient on full dose or prophylactic anticoagulation are eligible)
Thrombotic or thromboembolic events within the past 6 months:
History of arterial thromboembolic disease within 6 months of first study treatment
History of a thrombotic or thromboembolic event (arterial or venous) in the past 6 months
Thromboembolic events,
Participants with evidence of active thromboembolic disease or a history of thromboembolism within the preceding 6 months (excluding thrombosis of a central line)
History of arterial or venous thromboembolic disease 6 months prior to screening
History of thromboembolic disease (history of varicose veins and superficial phlebitis is allowed)
Current thromboembolic disease requiring full-dose anticoagulation patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible
History of arterial or venous thromboembolic event within 12 months prior to study participation
Treatment of a thromboembolic event =< 6 months prior to randomization
Prior history of documented venous thromboembolic event within the last 5 years (excluding central line associated events whereby patients completed anticoagulation)
A history of thromboembolic disorder or cerebral vascular disease
Subjects must not have a history of myocardial infarction within 6 months or a history of arterial thromboembolic event within 3 months of the first dose of investigational agent.
History of thromboembolic or cerebrovascular events ? 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
History of arterial thrombotic or embolic events (within 6 months prior to study entry)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study registration
History of thromboembolic or cerebrovascular events ? 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli.
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, deep vein thrombosis or pulmonary embolus within 6 months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) or deep venous thrombosis (DVT) within 6 months of informed consent\r\n* Tumor or bland thrombus in hepatic vasculature is not a contraindication provided hepatic function criteria are met
Significant thrombotic or embolic events within 4 weeks prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 4 weeks prior to study day 1 and the patient is asymptomatic and stable on anti-coagulation therapy
FOR ALL PHASES (Ib AND II): Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before the start of study medication
Subjects diagnosed with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 3 months of start of study treatment
Thrombotic or embolic events;
Thrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent
Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or venous pulmonary embolism within 6 months before the start of study treatment; venous thrombotic events such as deep vein thrombosis within 3 months before the start of study treatment
Arterial thrombotic or embolic events such as cerebrovascular accident (including ischemic attacks) or hemoptysis within 6 months before the first dose of study drug.
Venous thrombotic events (eg, deep vein thrombosis) or pulmonary arterial events (eg, pulmonary embolism) within 3 months before the first dose of study drug. Patients with venous thrombotic events ?3 months before the first dose of study drug on stable anticoagulation therapy are eligible.
Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic, attacks, deep vein thrombosis (DVT) within the past 6 months
SORAFENIB\r\n* Major surgery, open biopsy, or significant traumatic injury within 30 days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past 6 months\r\n* Upper Extremity/Line associated DVTs which are adequately treated (line removed and/or patient anticoagulated) are eligible\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib
Significant thrombotic or embolic events within 3 months prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if the patient is clinically stable and has completed or is on stable anti-coagulation therapy
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before enrollment
Any documented history of clinically identifiable thrombotic, embolic, venous, or arterial events such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment\r\n* Note: Patients with an asymptomatic catheter-related thrombus or a tumor-associated thrombus of locally-involved vessels or with incidental asymptomatic filling defects identified on imaging are not excluded
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
Any documented history of thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism within 6 months prior to initiating study treatment\r\n* Note: patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study
Arterial thrombotic or embolic events such as a myocardial infarction or cerebrovascular accident (including transient ischemic attacks) within the 6 months prior to initiation of treatment; incidental clinically insignificant embolic phenomena that do not require anti-coagulants are not excluded; also, tumor-associated thrombus of locally-involved vessels does not count as an exclusion criterion
Sorafenib\r\n* Major surgery, open biopsy, or significant traumatic injury within 30 days\r\n* Non-healing wound, ulcer, or bone fracture\r\n* Thrombotic or embolic venous or arterial events, such as cerebrovascular accident, including transient ischemic attacks, arterial thrombosis, deep vein thrombosis and pulmonary embolism within the past 6 months\r\n* Uncontrolled hypertension\r\n* Active bleeding during screening\r\n* Hypersensitivity to sorafenib
Arterial or venous thrombotic events or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before randomization
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
Any documented history of clinically significant thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or pulmonary embolism necessitating therapeutic anticoagulation within 6 months prior to initiating study treatment; Note: Patients with a tumor-associated thrombus of locally-involved vessels should not be excluded from participating in the study
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before registration
Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of the study registration
Significant thrombotic or embolic events within 3 months prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 3 months prior to study day 1 and the patient has completed or is on stable anti-coagulation therapy
Patients with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks [TIAs]) within 6 months before randomization
Arterial or venous thrombotic or embolic events such as cerebral vascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before randomization (except for adequately treated catheter-related venous thrombosis occurring within 6 months before randomization).
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months of start of study treatment.
Any history of thrombotic cerebrovascular accident or other arterial thrombosis
History of thromboembolic or cerebrovascular events =< 6 months prior to starting study treatment, including transient ischemic attacks, cerebrovascular accidents, deep vein thrombosis or pulmonary emboli
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of study treatment start
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of informed consent
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism =< 6 months prior to randomization
Significant thrombotic or embolic events within 4 weeks prior to study day 1; significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack (TIA); catheter-related thrombosis is not a cause for exclusion; diagnosis of deep vein thrombosis or pulmonary embolism is allowed if it occurred > 4 weeks prior to study day 1 and the patient is asymptomatic and stable on anti-coagulation therapy
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism =< 6 months prior to registration
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
History of arterial thrombotic or embolic events (within 6 months prior to study entry)
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within 6 months of informed consent
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) within 6 months of informed consent
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication.
Arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within the 6 months before start of FOLFIRI
Thrombotic or embolic events such as cerebrovascular accident, deep vein thrombosis or pulmonary embolism. History of transient ischemic attack is allowed.
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of study registration.
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication (except for adequately treated catheter-related venous thrombosis occurring more than 1 month before the start of study medication).
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 3 months before start of study treatment. However, if a patient has recovered to ECOG performance status of ? 2 he/she may be enrolled provided that other eligibility criteria are met
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism that have initiated within 6 months of start of study treatment; stable, persistent events under appropriate management diagnosed > 6 months prior to treatment are allowed at the discretion of the investigator
Arterial or venous thrombotic or embolic events
Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 6 months prior to the initiation of study treatment.
History of arterial or venous thrombotic/embolic events =< 12 months prior to registration
Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before the start of study medication
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent; Note: subjects with recent deep vein thrombosis (DVT) who have been treated with therapeutic anticoagulating agents for at least 6 weeks prior to study treatment are eligible
Have had arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism within 3 months prior to the initiation of study treatment
Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment within 6 months of informed consent
